logo
The Whoop 5.0 is here to make fitness bands cool again

The Whoop 5.0 is here to make fitness bands cool again

Digital Trends08-05-2025

Table of Contents
Table of Contents Whoop 5.0 hardware Whoop 5.0 new features Whoop price tiers
The Whoop 5.0 is here to make fitness bands cool again. Unlike the best smartwatches, the Whoop does not have a screen and doesn't mirror anything from your phone, so it's distraction-free. While smart rings have taken a lot of fitness band functionality and put it on your finger, Whoop feels there's still plenty of life left in a primarily wrist-worn health tracker. With new hardware, new features, and a new subscription package, there's a lot to understand, so lets go through the Whoop 5.0.
Whoop 5.0 hardware
There are two versions of the new Whoop: the Whoop 5.0 and the Whoop MG. The Whoop MG has a medical-grade, Food and Drug Administration (FDA) approved electrocardiogram (ECG) feature which is missing from the Whoop 5.0. Otherwise, the two appear to be identical. The case is seven percent smaller than the Whoop 4.0, but retains the same unusual strap system, which clips around the main body.
Recommended Videos
The body contains a set of enhanced sensors, an upgraded haptic engine, improved accelerometer and gyroscope, and a redesigned processor that's 10 times more efficient than the previous model. This has enabled a 14 day battery life, plus another 14 days from the Wireless PowerPack. This is another idiosyncrasy carried over from the last Whoop, where the battery pack is required to charge the main body, and also acts as a battery pack for recharging on the move.
While the Whoop 5.0 is made for the wrist and you can get a variety of different straps for it, what makes it even more unusual is the range of sports clothing with special pockets for the Whoop 5.0. These include compression shirts, bralettes, briefs, and bike shorts. Other 'Pods' are available so you can wear the Whoop in other ways.
A brief hands-on with the Whoop MG better shows the reduction in size, as it feels lighter and less pronounced on your wrist. The clasp and strap is still a bit of a pain to adjust, and it's often a bit too tight or a bit too loose, but the strap is elasticated so it should gradually stretch to the correct size. The most premium fabric strap is attached to the Whoop MG and mine comes in black with a silver clasp, and it looks modern and cool. As before though, the Whoop takes up wrist space without providing the time or any other information, so you may choose to wear it opposite a watch.
Whoop 5.0 new features
Wear the Whoop 5.0 to track more than 145 different activities, count your daily steps, and measure specific data points like V02 Max and muscular strain during strength training workouts, plus overnight to measure sleep and receive a Sleep Score based on a revised algorithm to better reflect sleep quality. The Whoop 5.0 also has cycle tracking with insights into hormonal shifts and how they affect sleep, stress, and recovery.
Beyond these basics, the Whoop 5.0 will show a new data set called Healthspan. It's geared more towards long-term health, and examines nine different metrics to calculate your Whoop Age and Pace of Aging. Whoop claims it goes further than any estimates of your cardiovascular age, and comes with its own personalized advice to help you improve long-term health.
Using a new technology, the Whoop 5.0 will be able to estimate your blood pressure too, after calibrating the band using a traditional blood pressure monitor. Finally, the ECG feature looks for irregular heart rhythms and will alert the wearer if any abnormalities are noticed. In the future there will also be the option to book blood tests and have the results directly integrate into the Whoop app.
Whoop price tiers
If all this sounds good, now we get to the part where some confusion and frustration may set in, because Whoop is introducing a new subscription system with the band, and it's based on the features you require. There are three price tiers — Whoop One, Whoop Peak, and Whoop Life — and access to features differ depending on the one you choose. The Whoop band is included in the price, and there's a lifetime warranty for it with all three plans. It's easier to show the differences in a table. For reference, an O indicates the feature is included, while an X indicates it is not available on that plan.
Feature Whoop One Whoop Peak Whoop Life Sleep, Strain, and Recovery O O O Personalized Coaching O O O V02 Max/Heart Rate Zones O O O Cycle Tracking O O O Healthspan and Pace of Aging X O O Health Monitor/Health Alerts X O O Real-time Stress Monitor X O O Blood Pressure X X O ECG and Heart Screener X X O Advanced Health Sensing X X O Strap CoreKnit SuperKnit SuperKnit Luxe Charger Basic Wired Waterproof Wireless PowerPack Waterproof Wireless PowerPack Price $199 per year $239 per year $359 per year
What it means is, if you want the full Whoop experience with the ECG monitoring, blood pressure, and the rather nebulous Advanced Health Sensing you have to select the top package. It's also worth noting if you're interested in the blood test feature, it will be an additional cost regardless of which tier you select, but it will be available on all of them. Some features, such as the ECG Heart Screener and blood test results are region specific. Whoop 5.0 is available to buy from Whoop's website, Amazon, and retailers including Best Buy.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

FDA grants 510(k) clearance to Viz.ai's Viz Subdural Plus module
FDA grants 510(k) clearance to Viz.ai's Viz Subdural Plus module

Yahoo

time2 days ago

  • Yahoo

FDA grants 510(k) clearance to Viz.ai's Viz Subdural Plus module

The US Food and Drug Administration (FDA) has granted 510(k) clearance to for its Viz Subdural Plus module, designed for enhancing clinical decision-making. It is claimed to be the first solution to quantify the size of collections such as subdural haemorrhages (SDH) in the subdural space on non-contrast computed tomography images. This solution automatically labels subdural collections and reports measurements such as thickness, midline shift, and volume. According to the company, chronic subdural haematoma is anticipated to become the most prevalent cranial neurosurgical condition in the adult population by 2030 in the US, with an estimated 60,000 new cases each year. The precise assessment of subdural collections is crucial for assessing severity, tracking progression, and guiding timely interventions, particularly for those under consideration for MMA [middle meningeal artery] embolisation. The software solution is designed to streamline the analysis of subdural collections by automating a process that has traditionally been manual and laborious. Integrated into the One platform, the software is currently in use in 1,800 health systems and hospitals. The platform enhances disease detection, supports critical care decisions, and optimises care pathways to improve patient outcomes. product management senior director Justin Ryea said: 'With an ageing population, the incidence of chronic subdural hematomas is rising, and so is the need for intelligent, automated tools to assess volume when deciding on the appropriate intervention such as MMA embolisation. 'Viz Subdural Plus, along with intracerebral haemorrhage measurements, exemplify how we're expanding our capabilities in our market-leading Viz Neuro Suite to address high-impact conditions, reduce variability in care, and drive better outcomes at scale.' The company leverages AI algorithms and machine learning to expedite diagnosis and care in the US and European healthcare systems. Last year, disclosed new trial data evaluating its AI-powered neurovascular technology that can detect and diagnose various neurological pathologies, including acute ischemic stroke, cryptogenic stroke, unruptured incidental aneurysm (UIA), and brain haemorrhage. "FDA grants 510(k) clearance to Viz Subdural Plus module" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

FDA grants 510(k) clearance to Viz.ai's Viz Subdural Plus module
FDA grants 510(k) clearance to Viz.ai's Viz Subdural Plus module

Yahoo

time2 days ago

  • Yahoo

FDA grants 510(k) clearance to Viz.ai's Viz Subdural Plus module

The US Food and Drug Administration (FDA) has granted 510(k) clearance to for its Viz Subdural Plus module, designed for enhancing clinical decision-making. It is claimed to be the first solution to quantify the size of collections such as subdural haemorrhages (SDH) in the subdural space on non-contrast computed tomography images. This solution automatically labels subdural collections and reports measurements such as thickness, midline shift, and volume. According to the company, chronic subdural haematoma is anticipated to become the most prevalent cranial neurosurgical condition in the adult population by 2030 in the US, with an estimated 60,000 new cases each year. The precise assessment of subdural collections is crucial for assessing severity, tracking progression, and guiding timely interventions, particularly for those under consideration for MMA [middle meningeal artery] embolisation. The software solution is designed to streamline the analysis of subdural collections by automating a process that has traditionally been manual and laborious. Integrated into the One platform, the software is currently in use in 1,800 health systems and hospitals. The platform enhances disease detection, supports critical care decisions, and optimises care pathways to improve patient outcomes. product management senior director Justin Ryea said: 'With an ageing population, the incidence of chronic subdural hematomas is rising, and so is the need for intelligent, automated tools to assess volume when deciding on the appropriate intervention such as MMA embolisation. 'Viz Subdural Plus, along with intracerebral haemorrhage measurements, exemplify how we're expanding our capabilities in our market-leading Viz Neuro Suite to address high-impact conditions, reduce variability in care, and drive better outcomes at scale.' The company leverages AI algorithms and machine learning to expedite diagnosis and care in the US and European healthcare systems. Last year, disclosed new trial data evaluating its AI-powered neurovascular technology that can detect and diagnose various neurological pathologies, including acute ischemic stroke, cryptogenic stroke, unruptured incidental aneurysm (UIA), and brain haemorrhage. "FDA grants 510(k) clearance to Viz Subdural Plus module" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data

Revolutionizing Diagnostics: Digital Pathology Market Growth Report  Reach US$1.73 billion by 2030 at 8.0% CAGR
Revolutionizing Diagnostics: Digital Pathology Market Growth Report  Reach US$1.73 billion by 2030 at 8.0% CAGR

Yahoo

time2 days ago

  • Yahoo

Revolutionizing Diagnostics: Digital Pathology Market Growth Report Reach US$1.73 billion by 2030 at 8.0% CAGR

CHICAGO, June 13, 2025 /PRNewswire/ -- The Global Digital Pathology Market is projected to be valued at USD 1.10 billion in 2024 and reach USD 1.73 billion by 2030, growing at a CAGR of 8% according to a new report by The Research Insights. The key driver of this growth is the mounting need for telepathology to enable pathologists to remotely view slides and interact live over distances. The other factor is integrating artificial intelligence (AI) in digital pathology systems, boosting diagnostics through automated image analysis and predictive analytics. The report runs an in-depth analysis of market trends, key players, and future opportunities. In general, the Digital Pathology Market growth of 8.0% comprises a vast array of Product, Type, Application, End-Use, and Geography which are expected to register strength during the coming years. For More Information and To Stay Updated on The Latest Developments in The Global Digital Pathology Market, Download FREE Sample Pages: Market Overview and Growth Trajectory: Digital Pathology Market Growth: According to an exhaustive report by The Research Insights, the Digital Pathology Market is experiencing significant growth. The worldwide digital pathology market expansion results from multiple technological advancements alongside clinical and systemic changes that mirror a comprehensive shift in diagnostic methods and healthcare service delivery. The rapid integration of artificial intelligence (AI) and machine learning algorithms serves as a key driving force in pathology because they improve diagnostic accuracy while enhancing workflow efficiency and decision-making support. Precision medicine's rising requirement along with individually tailored treatment plans drives the need for digital platforms that integrate histopathological data with genomic and clinical information. The worldwide scarcity of pathologists in developing markets forces healthcare infrastructures to implement digital pathology systems that consolidate diagnostic capabilities and allow for remote consultations through telepathology. The global rise in cancer cases demands the development of diagnostic solutions that operate more quickly and can scale to meet increasing needs. The FDA's regulatory approvals and standardization efforts are helping to validate digital pathology systems which leads to their broader use. The focus on digital health infrastructure and remote healthcare solutions after COVID-19 has solidified digital pathology's essential role in modern diagnostic processes. Rising Prevalence of Chronic Diseases and Cancer:The increasing global prevalence of chronic illnesses such as cancer alongside cardiovascular and autoimmune diseases creates demand for digital pathology through the need for accurate diagnostic results. Cancer stands as a primary focus area because the World Health Organization (WHO) reports that it causes almost 10 million deaths each year. The growing number of cancer cases increases the need for precise histopathological assessments which play a critical role in cancer staging and treatment planning as well as determining patient glass-slide microscopy requires extensive time commitment while demanding substantial labor effort and remains susceptible to mistakes by human operators. Digital pathology allows for complete slide digitization which supports storage capabilities as well as analysis and sharing functions. Digital platforms play an essential role in oncology and chronic disease management through improved diagnostic accuracy and simpler access to second opinions and telepathology. The requirement for high-throughput pathology services becomes even stronger when centralized laboratories need to serve extensive populations. For Detailed Market Insights, Visit: Innovations in Whole Slide Imaging (WSI) technology combined with artificial intelligence (AI) integration are driving major changes in digital pathology:Progress in imaging technology alongside improvements in data storage and artificial intelligence (AI) development is revolutionizing digital pathology. The development of Whole Slide Imaging (WSI) now enables the capture of ultra-high-resolution images which can be stored and distributed with very little delay. After digitization these images become suitable for AI analysis which helps detect patterns and anomalies while classifying tissue types with greater consistency than manual workflows now frequently utilize AI-powered tools to help pathologists identify diseases at early stages while simultaneously quantifying biomarkers and standardizing interpretations. The algorithms designed for breast and prostate cancer detection improve diagnostic efficiency and minimize inter-observer variability by highlighting suspicious regions and providing grading suggestions. Real-time slide sharing capabilities of cloud-based platforms allow institutions to collaborate on diagnostics without being limited by geographic distances. This technological progress improves diagnostic speed and accuracy while shortening turnaround time which is essential for treating life-threatening conditions. Growing Adoption of Telepathology and Remote Consultations:The pandemic hastened digital health technology implementation with digital pathology becoming another beneficiary of this trend. Telepathology has become an essential diagnostic tool due to increasing demands for remote consultations and second opinions. Digital platforms now enable hospitals and laboratories to share slides across regions and countries with specialists which allows for expert reviews and collaborations to occur promptly without needing to transport specimens is emerging as a critical solution to the worldwide inequality in pathology services. Rural regions and areas with limited resources experience a significant lack of trained pathologists. Through digital pathology centralized specialists review cases from distant locations which closes existing healthcare gaps to advance healthcare equity. Digital pathology platforms provide educational institutions with benefits for training and research because students and researchers can access actual slides from any location at any time. Stay Updated on The Latest Digital Pathology Market Trends: Geographical Insights: The North American market achieved a 40.7% share of the global market in 2023 because government-backed initiatives advanced pathology technology. The dominance resulted from continuous R&D funding and the growing implementation of digital imaging technologies. Their influence grew stronger in the region because prominent players focused on creating innovative solutions to meet the needs of the local population. Market expansion is propelled by academic research and disease diagnosis needs for digital pathology because institutions aim to use its capabilities to enhance diagnostic accuracy and treatment results. Between 2024 and 2030 the Asia Pacific region will achieve the highest Compound Annual Growth Rate (CAGR) thanks to increased digitalization activities combined with medical research investments and the growing use of digital imaging technologies in developing economies. The rising occurrence of cancer cases continues to drive market growth which highlights the necessity for new treatment options that will advance market expansion. Global Digital Pathology Market Segmentation and Geographical Insights: Based on Product, the digital pathology market is divided into, Software, Device, and Storage System. The device segment dominated the market share in 2023 with 51.72% and is expected to experience substantial growth over the projected period. Based on Type, the digital pathology market is divided into, Human Pathology, and Veterinary Pathology. The human aspect of digital pathology is playing a pivotal role, accounting for approximately 60.0% market share in 2023. Based on Application, the digital pathology market is divided into, Drug Discovery & Development, Academic Research, and Disease Diagnosis. The academic research segment led the market share in 2023, accounting for 45.7%, and is expected to continue its dominance from 2024 to 2030 due to ongoing research in cancer therapy development and high adoption rates of digital pathology in various studies. Based on End Use, the digital pathology market is divided into, Hospitals, Biotech & Pharma Companies, Diagnostic Labs, and Academic & Research Institutes. The healthcare sector led the market share in 2023 with a notable presence of 36.7%. The Digital Pathology Market is segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Purchase Premium Copy of Global Digital Pathology Market Size and Growth Report (2024-2030) at: Key Players and Competitive Landscape: The Global Digital Pathology Market is characterized by the presence of several major players, including: Leica Biosystems Nussloch GmbH (Danaher) Hamamatsu Photonics, Inc. Koninklijke Philips N.V. Olympus Corporation F. Hoffmann-La Roche Ltd. Mikroscan Technologies, Inc. Inspirata, Inc. Epredia (3DHISTECH Ltd.) Visiopharm A/S Huron Technologies International Inc. ContextVision AB CellaVision HANGZHOU ZHIWEI INFORMATION TECHNOLOGY CO. LTD. (MORPHOGO) West Medica Produktions- und Handels- GmbH (West Medica) aetherAI IBEX (IBEX MEDICAL ANALYTICS) SigTuple Technologies Private Limited Morphle Labs, Inc Bionovation Biotech, Inc. These companies are adopting strategies such as new product launches, joint ventures, and geographical expansion to maintain their competitive edge in the market. Global Digital Pathology Market Recent Developments and Innovations: In March 2024: Koninklijke Philips N.V. (Netherlands) formed an expanded partnership with AWS to create secure, scalable cloud-based digital pathology solutions. The collaboration between AWS and Philips will improve workflow efficiency while ensuring smooth integration with current healthcare systems to provide complete patient care. In February 2024: Roche entered into a partnership with Path AI to build an AI-powered digital pathology algorithm for companion diagnostics. Through this partnership Roche will speed up its capacity to fulfill biopharma companies' needs who seek to create AI-driven companion diagnostics and deliver complete solutions. In March 2023: Agilent Technologies partnered with Hamamatsu Photonics K.K. Agilent Technologies teamed up with Hamamatsu Photonics K.K. to integrate the NanoZoomer range with the S360MD Slide scanner system into their comprehensive digital pathology solution. In March 2022: Roche Diagnostics partnered with SRL Diagnostics. In collaboration with Roche Diagnostics, SRL Diagnostics intended to upgrade its Fortis Memorial Research Institute laboratory facilities. For Region-Specific Market Data, Check Out Brief Sample Pages: Frequently Asked Questions (FAQs): What is the forecasted market size of the Digital Pathology Market in 2030? The forecasted market size of the Digital Pathology Market is USD 1.73 billion in 2030. Who are the leading players in the Digital Pathology Market? The key players in the Digital Pathology Market include, Leica Biosystems Nussloch GmbH (Danaher); Hamamatsu Photonics, Inc.; Koninklijke Philips N.V.; Olympus Corp.; F. Hoffmann-La Roche Ltd.; Mikroscan Technologies, Inc.; Inspirata, Inc.; Epredia (3DHISTECH Ltd.); Visiopharm A/S; Huron Technologies International Inc.; ContextVision AB; HANGZHOU ZHIWEI INFORMATION TECHNOLOGY CO. LTD. (MORPHOGO); West Medica Produktions- und Handels- GmbH (West Medica); aetherAI; IBEX (IBEX MEDICAL ANALYTICS); SigTuple Technologies Private Limited; Morphle Labs, Inc; and Bionovation Biotech, Inc. What are the major drivers for the Digital Pathology Market? Several key factors are driving this expansion, including the growing adoption of AI-enabled digital pathology. Which is the largest region during the forecasted period in the Digital Pathology Market? The North American market achieved a 40.7% share of the global market in 2023 because government-backed initiatives advanced pathology technology. Which is the largest segment, by product, during the forecasted period in the Digital Pathology Market? The device segment dominated the market share in 2023 with 51.72% and is expected to experience substantial growth over the projected period. Conclusion: Digital imaging advancements and AI along with data analytics improvements lead to major transformations within the global digital pathology market which meets healthcare systems' needs for swifter and more precise diagnostic procedures. The spread of chronic diseases combined with telepathology demand growth and pathologist workforce deficits has sped up the implementation of digital pathology technologies. Modern systems provide the ability for immediate remote medical consultations alongside more efficient data exchange and better-informed decisions through artificial intelligence that analyses medical images. The combination of EHR integration with advanced interoperability and cloud storage solutions leads to better diagnostic precision and operational efficiency. Digital pathology stands as a fundamental component of precision medicine and laboratory automation while global healthcare digitization progresses alongside evolving regulatory frameworks and advanced data security technologies. The market's growth momentum continues as it connects with wider digital health movements and shifts towards value-based care approaches. Need A Diverse Region or Sector? Customize Research to Suit Your Requirement: The report from The Research Insights, therefore, provides several stakeholders—healthcare providers, diagnostic laboratories, research institutions, pharmaceutical companies, and regulatory agencies—with valuable insights into how to successfully navigate this evolving market landscape and unlock new opportunities. With projected growth to US$ 1.73 billion by 2030, the Global Digital Pathology Market represents a significant opportunity for AI technology developers, cloud service providers, medical imaging software companies, digital health startups, and telepathology platform vendors. Check out more related studies published by The Research Insights: U.S. And Europe Digital Pathology Market - The US and European digital pathology market is poised for significant growth, driven by increasing efforts to harness this technology for enhanced disease diagnosis and improved pathology practices. Currently valued at USD 578.6 million in 2022, the market is projected to expand at a compound annual growth rate (CAGR) of 7.2% from 2023 to 2030. In the US, the FDA has classified digital pathology as Class II devices suitable for primary diagnosis, paving the way for wider adoption. Pathology Laboratories Market: The Global Pathology Laboratories Market is expected to reach at USD 612.22 billion by 2030, according to a new report by The Research Insights. It is projected to expand at a CAGR of 8.1% during the forecast period. This growth is driven by the expanding healthcare infrastructure in developing countries, as well as an increasing demand for regular medical check-ups and enhanced reimbursement policies for diagnostic tests. AI in Pathology Market - The AI in Pathology Market size is set to grow from USD 92.32 million in 2025 to USD 434.16 million by 2034, at a CAGR of 19.07%. The AI for Pathology Market describes how artificial intelligence technologies including machine learning algorithms and neural networks process pathology data to aid clinical decision-making while boosting diagnostic precision and workflow productivity. The medical field of pathology which focuses on disease study and diagnosis through tissue, organ, and fluid examination is experiencing a digital shift through AI integration. Anatomic Pathology Market - The global anatomic pathology market continues to expand its reach, with valued sales reaching USD 30.16 billion in 2022. As we look ahead, the market is projected to experience a significant compound annual growth rate (CAGR) of 8.7% from 2023 to 2030. This surge in growth can be attributed to the increasing adoption of biomarkers in clinical settings, which has revolutionized the way pathologists analyze molecular-level mechanisms. Precision Pathology for Cancer Market: The Research Insights report reveals that Precision pathology for cancer applies advanced technological methods to produce customized diagnostic and therapeutic approaches based on individual tumor biology. This innovative method combines histological, genomic and bioinformatic knowledge to enable healthcare providers to develop individualized treatment plans which lead to improved patient results. Browse More related reports on Healthcare Industry Market Reports – About Us: The Research Insights provides thoroughly conducted research which is backed up by real-time statistics and data. Our experts are eager to help you with any information required under the sun. The key to our success is keeping abreast with the markets, industries, and ever-changing consumer trends that matter. Our market research professionals have in-depth knowledge and expertise across various domains that includes IT and Telecom, Emerging Technologies, Consumer Offerings, Manufacturing and Others. We are committed to reviewing the scope and procedure of the research studies that you select and provide you with an accurate guidance in order to assist you in taking the correct business decisions. Contact Us:If you have any queries about this report or if you would like further information, please contact us: Contact Person: Kaushik RoyE-mail: sales@ +1-312-313-8080Blog: Release: News: | Logo: View original content: SOURCE The Research Insights

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store